Third quarter 2026
Filed Nov 4, 2026Clover Health reported third quarter 2026 GAAP net income of $6 million, total revenues of $759 million, and raised full-year 2026 guidance across all disclosed metrics.
Third-quarter revenue increased 52.9%, GAAP net income improved to $6.4 million from a $24.4 million loss, consolidated gross profit increased 77.3%, and the company raised the low end of full-year guidance for revenue, GAAP net income, consolidated gross profit, Adjusted EBITDA, and average Medicare Advantage membership.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $759.3M | – | 52.9% |
| Premiums earned, net, three months ended September 30, 2026GAAP | $748.8M | – | – |
| Other income, three months ended September 30, 2026GAAP | $10.52M | – | – |
| Net medical claims incurred, three months ended September 30, 2026GAAP | $629.5M | – | – |
| Consolidated Gross profit, three months ended September 30, 2026non-GAAP | $129.8M | – | 77.3% |
| Salaries and benefits, three months ended September 30, 2026GAAP | $55.97M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $66.83M | – | – |
| SG&A, three months ended September 30, 2026GAAP | $122.8M | – | 26.5% |
| Adjusted SG&A, three months ended September 30, 2026non-GAAP | $113.8M | – | 60.1% |
| Adjusted SG&A as a percentage of Total revenues, three months ended September 30, 2026non-GAAP | 15.0% | – | 70 bps |
| Depreciation and amortization, three months ended September 30, 2026GAAP | $610K | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $752.9M | – | – |
| Income (loss) from operations, three months ended September 30, 2026GAAP | $6.43M | – | – |
| Net income (loss), three months ended September 30, 2026GAAP | $6.4M | – | N/A* |
| Basic earnings (loss) per share, three months ended September 30, 2026GAAP | $0.01 | – | – |
| Diluted earnings (loss) per share, three months ended September 30, 2026GAAP | $0.01 | – | – |
| Comprehensive income (loss), three months ended September 30, 2026GAAP | $4.63M | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $16.1M | – | 666.7% |
| Adjusted Net income, three months ended September 30, 2026non-GAAP | $15.4M | – | 805.9% |
| Insurance Benefits Expense Ratio, three months ended September 30, 2026non-GAAP | 91.1% | – | (240 bps) |
| Average Medicare Advantage membership, three months ended September 30, 2026other | 158,383 | – | 46.3% |
| Total revenues, nine months ended September 30, 2026GAAP | $2.25B | – | 56.7% |
| Consolidated Gross profit, nine months ended September 30, 2026non-GAAP | $442.4M | – | 57.0% |
| SG&A, nine months ended September 30, 2026GAAP | $378.9M | – | 19.7% |
| Adjusted SG&A, nine months ended September 30, 2026non-GAAP | $345.2M | – | 45.8% |
| Adjusted SG&A as a percentage of Total revenues, nine months ended September 30, 2026non-GAAP | 15.3% | – | (120 bps) |
| Net income (loss), nine months ended September 30, 2026GAAP | $61.8M | – | N/A* |
| Basic earnings (loss) per share, nine months ended September 30, 2026GAAP | $0.12 | – | – |
| Diluted earnings (loss) per share, nine months ended September 30, 2026GAAP | $0.11 | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $97.2M | – | 116.0% |
| Adjusted Net income, nine months ended September 30, 2026non-GAAP | $95.5M | – | 118.5% |
| Insurance Benefits Expense Ratio, nine months ended September 30, 2026non-GAAP | 88.4% | – | (100 bps) |
| Average Medicare Advantage membership, nine months ended September 30, 2026other | 156,610 | – | 48.8% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Insurance Segment, three months ended September 30, 2026Average Medicare Advantage membership was 158,383, up 46.3% year-over-year; Insurance BER was 91.1%, compared with 93.5%. | $748.8M | – | 56.3% |
| Insurance Segment, nine months ended September 30, 2026Average Medicare Advantage membership was 156,610, up 48.8% year-over-year; Insurance BER was 88.4%, compared with 89.4%. | $2.23B | – | 58.7% |
Full Year 2026 outlook
- Revenue$2.97 billion - $3.00 billion
- NoteGAAP Net income: $25 million - $35 million
- NoteConsolidated Gross profit: $540 million - $555 million
- NoteAdjusted EBITDA: $75 million - $85 million
- NoteAverage Medicare Advantage membership: 157,000 - 158,000
Capital returns
- Repurchases of common stock: — for the nine months ended September 30, 2026.
- Cash paid for shares withheld related to stock-based compensation: $(9,680) thousand for the nine months ended September 30, 2026.
What drove it
- Third-quarter average Medicare Advantage membership was 158,383, up 46.3% year-over-year.
- Insurance revenue was $748.8 million, up 56.3% year-over-year in the third quarter.
- Insurance BER improved by (240 bps) year-over-year to 91.1% in the third quarter.
- The flagship PPO represented ~98% of current membership and received a 5 Star rating for Payment Year 2028.
- Management cited maturing member cohorts, continued operating leverage, and strong Star ratings performance in its outlook for 2027.
Concerns
- Other income was $10,520 thousand in the third quarter, compared with $17,522 thousand in the prior-year period.
- Adjusted SG&A as a percentage of Total revenues was 15.0% in the third quarter, compared with 14.3% in the prior-year period.
- Unpaid claims were $269,101 thousand at September 30, 2026, compared with $153,250 thousand at December 31, 2025.
- Third-quarter Insurance BER of 91.1% was higher than the 88.4% reported for the nine months ended September 30, 2026.
What to watch
- Full-year 2026 total revenues guidance of $2.97 billion - $3.00 billion.
- Full-year 2026 GAAP Net income guidance of $25 million - $35 million.
- Full-year 2026 Consolidated Gross profit guidance of $540 million - $555 million.
- Full-year 2026 Adjusted EBITDA guidance of $75 million - $85 million.
- Average Medicare Advantage membership guidance of 157,000 - 158,000.
- 2027 AEP tracking and the effect of the 5 Star rating for Payment Year 2028.
Balance sheet and cash flow
- Total cash, cash equivalents, and investments: $512.6 million at September 30, 2026, compared with $395.9 million at September 30, 2025.
- Cash and cash equivalents: $268,067 thousand at September 30, 2026, compared with $78,301 thousand at December 31, 2025.
- Total assets: $753,680 thousand at September 30, 2026, compared with $541,011 thousand at December 31, 2025.
- Total liabilities: $362,808 thousand at September 30, 2026, compared with $232,307 thousand at December 31, 2025.
- Net cash provided by operating activities: $203,462 thousand for the nine months ended September 30, 2026, compared with $1,218 thousand.
- Purchases of property and equipment: $(2,434) thousand for the nine months ended September 30, 2026, compared with $(1,446) thousand.
- Net cash used in investing activities: $(7,976) thousand for the nine months ended September 30, 2026, compared with $39,071 thousand provided by investing activities.
- Net cash used in financing activities: $(5,720) thousand for the nine months ended September 30, 2026, compared with $(44,777) thousand.
- Net increase in cash and cash equivalents: $189,766 thousand for the nine months ended September 30, 2026, compared with a net decrease of $(4,488) thousand.
Analysis
Clover Health delivered strong third-quarter growth and a return to GAAP profitability. Total revenues increased 52.9% to $759.3 million, while average Medicare Advantage membership increased 46.3% to 158,383. Insurance revenue increased 56.3% to $748.8 million. Third-quarter GAAP net income was $6.4 million, compared with a loss of $(24.4) million in the prior-year period, while Adjusted EBITDA increased to $16.1 million from $2.1 million.
Medical-cost performance improved year over year. Consolidated Gross profit increased 77.3% to $129.8 million, outpacing revenue growth, and the Insurance BER improved by (240 bps) to 91.1%. The nine-month Insurance BER was 88.4%, compared with 89.4% in the prior-year period. These results accompanied 56.7% nine-month revenue growth to $2,251.7 million and nine-month GAAP net income of $61.8 million, compared with a $(36.2) million loss.
Expense trends show both operating leverage and areas requiring attention. GAAP SG&A increased 26.5% to $122.8 million in the quarter, materially slower than revenue growth. However, Adjusted SG&A increased 60.1% to $113.8 million, and Adjusted SG&A as a percentage of Total revenues increased to 15.0% from 14.3%. Other income declined to $10,520 thousand from $17,522 thousand. Unpaid claims rose to $269,101 thousand at September 30, 2026, from $153,250 thousand at December 31, 2025.
Liquidity increased during the nine-month period. Total cash, cash equivalents, and investments were $512.6 million, compared with $395.9 million at September 30, 2025. Net cash provided by operating activities was $203,462 thousand, compared with $1,218 thousand in the prior-year period. Cash and cash equivalents ended the period at $268,067 thousand, up from $78,301 thousand at December 31, 2025.
The company raised the low end of all disclosed full-year 2026 guidance ranges. Revenue guidance is now $2.97 billion - $3.00 billion, GAAP Net income guidance is $25 million - $35 million, Consolidated Gross profit guidance is $540 million - $555 million, Adjusted EBITDA guidance is $75 million - $85 million, and average Medicare Advantage membership guidance is 157,000 - 158,000. Management also highlighted 2027 AEP tracking, maturing member cohorts, operating leverage, and the 5 Star rating for its flagship PPO for Payment Year 2028.
Management, verbatim
Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.
Andrew Toy, Clover Health CEO
Through Clover Assistant, we are committed to delivering better clinical quality and lower total cost of care. We are pleased that this continues to show up in our results, with ~98% of our members enrolled in our 5 Star rated PPO for Payment Year 2028, alongside our third consecutive year of nation-leading HEDIS performance.
Andrew Toy, Clover Health CEO
In 2026, Clover is on track to have grown significantly and expects to deliver its first full year of GAAP Net Income profitability.
Clay Thornton, Clover Health CFO
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported quarterly metrics were not provided.
- Free cash flow was not reported.
- Debt was not reported.
- Dividends were not reported.
- Non-GAAP earnings per share were not reported.
- Gross margin was not reported.
- Operating margin was not reported.
- Forward guidance for gross margin, operating expenses, and tax rate was not provided.
- The previous outlook covered the full year 2026 only, and this quarterly release cannot be compared with full-year guidance.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.